<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00459836</url>
  </required_header>
  <id_info>
    <org_study_id>PR104-1003</org_study_id>
    <secondary_id>PROACTA-PR-104-1003</secondary_id>
    <secondary_id>PROACTA-WIRB-20070094</secondary_id>
    <nct_id>NCT00459836</nct_id>
  </id_info>
  <brief_title>PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors</brief_title>
  <official_title>A Phase Ib, Multi-Center, Open-Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination With Docetaxel or Gemcitabine in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proacta, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Proacta, Incorporated</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as PR-104, docetaxel, and gemcitabine, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of PR-104 when given&#xD;
      together with docetaxel or gemcitabine in treating patients with solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of PR-104 in combination with docetaxel or&#xD;
           gemcitabine hydrochloride in patients with solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety of PR-104 in combination with docetaxel or gemcitabine&#xD;
           hydrochloride in these patients.&#xD;
&#xD;
        -  Determine the antitumor activity of these regimens using disease-specific parameters,&#xD;
           such as exams, scans, and tumor markers, in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of PR-104 and its alcohol metabolite in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of docetaxel and gemcitabine hydrochloride when&#xD;
           administered with PR-104.&#xD;
&#xD;
        -  Collect plasma samples for assessment of potential biomarkers of tumor hypoxia from&#xD;
           these patients.&#xD;
&#xD;
        -  Examine metabolic changes in tumors using fludeoxyglucose F 18 positron emission&#xD;
           tomography (PET) and PET imaging with fluoromisonidazole F 18 (a hypoxia-targeted&#xD;
           radiopharmaceutical) in these patients.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, uncontrolled, multicenter, dose-escalation&#xD;
      study of PR-104. Patients are assigned to 1 of 2 treatment groups according to patient's&#xD;
      malignancy and prior treatment history.&#xD;
&#xD;
        -  Group 1: Patients receive docetaxel IV over 60 minutes and PR-104 IV over 60 minutes on&#xD;
           day 1.&#xD;
&#xD;
        -  Group 2: Patients receive gemcitabine hydrochloride IV over 30 minutes and PR-104 IV&#xD;
           over 60 minutes on days 1 and 8.&#xD;
&#xD;
      In both groups, treatment repeats every 21 days for up to 8 courses in the absence of&#xD;
      unacceptable toxicity or disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients in each group receive escalating doses of PR-104 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Blood is collected at baseline and periodically during course 1 for pharmacokinetic analysis.&#xD;
      Plasma samples are analyzed for biomarkers of tumor hypoxia at baseline and on days 2 and 8.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of PR-104</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of PR-104 as measured by CTCAE v3.0 criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicity of PR-104</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PR-104 and its alcohol metabolite in the blood</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of gemcitabine and docetaxel in the presence of PR-104</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
  </secondary_outcome>
  <enrollment type="Actual">42</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR-104</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor malignancy&#xD;
&#xD;
          -  Treatment with either docetaxel or gemcitabine hydrochloride in combination with an&#xD;
             investigational agent is reasonable&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status of 0-1&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL (red blood cell transfusion allowed)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  PT/INR or aPTT ≤ 1.1 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  No evidence of any other significant medical disorder, including uncontrolled&#xD;
             infection or infection requiring a concurrent parenteral antibiotic, or laboratory&#xD;
             finding that, in the opinion of the investigator, would preclude study compliance&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No hepatitis B surface antigen positivity&#xD;
&#xD;
          -  No hepatitis C positivity with abnormal liver function test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of bone marrow&#xD;
&#xD;
          -  No prior high-dose chemotherapy (including conditioning for either myeloablative or&#xD;
             nonmyeloablative transplantation)&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  More than 4 weeks since prior investigational or traditional anticancer therapy&#xD;
             (including radiotherapy) (6 weeks for nitrosoureas and mitomycin C)&#xD;
&#xD;
          -  The following medications/treatments are not permitted during the trial:&#xD;
&#xD;
               -  Any other licensed or investigational anticancer treatment&#xD;
&#xD;
               -  Prophylactic hematopoietic growth factors&#xD;
&#xD;
               -  Irradiation therapy (palliative or therapeutic) unless given in the absence of&#xD;
                  tumor progression&#xD;
&#xD;
          -  Concurrent systemic steroids allowed provided the patient is on a stable dose for ≥ 2&#xD;
             weeks prior to study treatment&#xD;
&#xD;
          -  Concurrent androgen-deprivation therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terri J. Melink, NP, MSN, ANP</last_name>
    <role>Study Chair</role>
    <affiliation>Proacta, Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Proacta, Incorporated</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Auckland Cancer Center</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>2020</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>April 11, 2007</study_first_submitted>
  <study_first_submitted_qc>April 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2007</study_first_posted>
  <last_update_submitted>February 28, 2011</last_update_submitted>
  <last_update_submitted_qc>February 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Brenda Gibson, Assoc. Director</name_title>
    <organization>Proacta, Inc.</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

